FOLH1 and metastatic prostate carcinoma: Peptides are also proving to be valuable in cancer treatment and diagnostic imaging, like Lutetium Lu-177 Vipivotide Tetraxetan, a radiolabeled peptide targeting the prostate-specific membrane antigen (PSMA) for treating metastatic prostate cancer [12] and Gallium Ga-68 Gozetotide, a peptide-based imaging agent used in PET scans to visualize PSMA in prostate cancer patients [13].